Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H23N5O4 |
Molecular Weight | 481.5026 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(NC1=CC=CC2=C1OC(=CC2=O)C3=NN=NN3)C4=CC=C(OCCCCC5=CC=CC=C5)C=C4
InChI
InChIKey=NBQKINXMPLXUET-UHFFFAOYSA-N
InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
Molecular Formula | C27H23N5O4 |
Molecular Weight | 481.5026 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB01411Curator's Comment: description was created based on several sources, including
http://www.e-search.ne.jp/~jpr/PDF/ONO04.PDF
Sources: https://www.drugbank.ca/drugs/DB01411
Curator's Comment: description was created based on several sources, including
http://www.e-search.ne.jp/~jpr/PDF/ONO04.PDF
Pranlukast is an antagonist of cysteinyl leukotriene receptor-1 antagonist. It is marketed in Japan by Ono Pharmaceuticals under trademark ONON for the treatment of bronchial asthma and allergic rhinitis as capsules and dry syrup for pediatric use.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1798 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26985325 |
23.0 nM [IC50] | ||
Target ID: CHEMBL4330 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10851239 |
3620.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ONON Approved UseONON capsules are indicated for treatment of bronchial asthma |
|||
Primary | ONON Approved UseONON capsules are indicated for treatment of allergic rhinitis |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Cysteinyl leukotrienes induce P-selectin expression in human endothelial cells via a non-CysLT1 receptor-mediated mechanism. | 1997 May |
|
Therapeutic effect of pranlukast, a selective cysteinyl leukotriene receptor antagonist, on bronchial asthma. | 1997 Sep |
|
Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists. | 1998 Dec 15 |
|
Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. | 1998 Jun |
|
Pharmacology of leukotriene receptor antagonists. | 1998 Jun |
|
Inhibition of 5-lipoxygenase diminishes neurally evoked tachykinergic contraction of guinea pig isolated airway. | 1998 May |
|
Leukotriene C4 is a tight-binding inhibitor of microsomal glutathione transferase-1. Effects of leukotriene pathway modifiers. | 1999 Jan 22 |
|
Characterization of the human cysteinyl leukotriene CysLT1 receptor. | 1999 Jun 24 |
|
Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. | 1999 Mar |
|
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. | 1999 Sep |
|
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity. | 1999 Sep 20 |
|
A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lung parenchyma. | 2000 Jun |
|
Characterization of the human cysteinyl leukotriene 2 receptor. | 2000 Sep 29 |
|
Effects of pranlukast, a leukotriene receptor antagonist, on airway inflammation in mild asthmatics. | 2001 Feb |
|
Churg-Strauss syndrome after reduction of inhaled corticosteroid in a patient treated with pranlukast for asthma. | 2001 May |
|
Cysteinyl leukotriene receptor 1 is involved in N-methyl-D-aspartate-mediated neuronal injury in mice. | 2006 Dec |
|
Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. | 2011 Aug |
|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.e-search.ne.jp/~jpr/PDF/ONO04.PDF
The usual adult dosage for oral use is 450 mg of pranlukast hydrate (4 capsules) daily in two divided doses after each meal in the morning and evening. The dosage may be adjusted according to the patient's age and symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26985325
The activity of pranlukast was measured using calcium mobilization assay. HEK 293 cells stably expressing CysLT1 receptor and Gα16 protein were loaded with 2 uM Fluo-4 AM in Hanks balanced salt solution buffer. The compound was added to a solution, and after 10 min incubation at room temperature, 25 uL LTD4 was dispensed into the well using a FlexStation II microplate reader, and intracellular calcium change was recorded with an excitation wavelength of 485 nm and an emission wavelength of 525 nm. The IC50 for pranlukast was 23 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:34:48 GMT 2023
by
admin
on
Fri Dec 15 15:34:48 GMT 2023
|
Record UNII |
TB8Z891092
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QR03DC02
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
||
|
NCI_THESAURUS |
C29712
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
||
|
WHO-ATC |
R03DC02
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TB8Z891092
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
CHEMBL21333
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
m9100
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID3043782
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
4887
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
PRANLUKAST
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
100000091523
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
2237
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
6943
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
C96712
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
SUB09998MIG
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
C047681
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
3634
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
DB01411
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY | |||
|
103177-37-3
Created by
admin on Fri Dec 15 15:34:48 GMT 2023 , Edited by admin on Fri Dec 15 15:34:48 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|